Richard A. Ler,ner, M.D., President of the Scripps Research Institute, to Lead Dyadic Scientific Advisory Board

Jupiter, FL -- Dyadic International, Inc., a leading biotechnology company focused on protein expression, announced today that Dr. Richard A. Lerner, President of The Scripps Research Institute, has joined as the companys Chairman of the Scientific Advisory Board.

Jupiter, FL (PRWEB) February 29, 2004 --Dyadic International, Inc., a leading biotechnology company focused on protein expression, announced today that Dr. Richard A. Lerner, President of The Scripps Research Institute, has joined as the companys Chairman of the Scientific Advisory Board.

Dr. Lerners many scientific and business accomplishments are well-known," said Mark Emalfarb, President and CEO of Dyadic. Richards strategic leadership, combined with his proven ability for finding innovative ways to overcome scientific challenges, has turned Scripps into a preeminent research institution on the frontier of biomedical research. We are very pleased that he has agreed to chair the Scientific Advisory Board of Dyadic and we look forward to benefiting from his insights, experience and extensive scientific network as we advance our proprietary integrated C1 protein expression and gene discovery technology for introduction to the biopharmaceutical and other markets."

Through a lot of hard work, keen scientific observations and some serendipitous discoveries, Dyadic has reached an important point in the development of its paradigm shifting technology platform," commented Dr. Lerner. When fully developed, this technology will help lower the cost of prescription drugs by enabling biopharmaceutical researchers to work with a broader universe of genes, move potential cures stuck on the shelves at pharmaceutical companies into clinical development faster, and produce these drugs cost effectively on a commercial scale using the same organism in which they were discovered."

The opportunity to lead the Scientific Advisory Board of one of Floridas biotechnology pioneers is truly exciting and is a distinct honor," Dr. Lerner added. I look forward to working closely with Dyadics experienced team to accelerate the development of this unique technology to help discover and create new drugs and to make drugs more affordable, as well as to discover and develop other bioproducts that will address needs in many other diverse markets."

Dr. Lerner is Professor of Immunochemistry, Chair in Chemistry, and President of The Scripps Research Institute, one of the largest private, non-profit scientific research organizations in the world. Its staff includes 288 principal investigators, 775 postdoctoral fellows, 230 graduate students, and more than 1,500 technical and administrative staff. Among the senior staff, fourteen are members of the National Academy of Sciences and three are Nobel laureates. The Scripps Research Institute has recently announced plans to establish a major science center in Palm Beach County, Florida, focusing on biomedical research, technology development, and drug design.

Dr. Lerner is a world renowned expert in the field of catalytic antibodies, a field that takes as its principle goal an understanding of how the binding energy of proteins can be utilized to facilitate chemical transformations. Richard Lerner graduated from Northwestern University and Stanford Medical School and received his postdoctoral training at Scripps Clinic and Research Foundation in experimental pathology. Dr. Lerner has received numerous honors, including election to the National Academy of Sciences and the Royal Swedish Academy of Sciences, and receipt of the Wolf Prize in Chemistry.

About Dyadic

Dyadic International, Inc. is a privately held, venture capital backed biotechnology company. Dyadic has been executing its business plan by leveraging the considerable know-how, relationships, and cash flow from its profitable industrial enzyme business to develop its patented C1 gene discovery and expression platform technology. Dyadics Gene Discovery technology uses state-of-the-art robotic screening to identify and evolve therapeutically relevant genes. Dyadics Gene Expression system converts those genes into their protein products. Finally, utilizing its Product Development expertise and Large-scale Manufacturing know-how and alliances, Dyadic brings those products to market economically. All of the above technologies use a single biological host, Dyadics proprietary C1 fungal host system. This integrated platform provides a total package for bringing products from discovery to commercialization. Using this integrated technology platform also increases the odds of R&D success while shortening the timeline for new product and process development. Dyadic is using its proprietary technologies to discover, develop and manufacture commercial quantities of protein products and enzymes for applications in the pharmaceutical, biotechnology, textile, chemical, agricultural, pulp & paper and other industries.

For further information, contact:
Alexander Bondar
Executive Director, Business Development
Dyadic International, Inc.
140 Intracoastal Pointe Drive, Suite 404
Jupiter, FL 33477
phone    (561) 743-8333
fax   (561) 743-8343
sbondar@dyadic-group.com

http://www.dyadic-group.com